HeartFlow
Category: AI in Healthcare
A non-invasive, AI-powered precision coronary care platform that helps clinicians diagnose and treat heart disease using data from a standard coronary CT scan. HeartFlow was founded in 2007. The company is led by John Farquhar. Based in Redwood City, California, USA. Team size: 501-1000. Total funding raised: Over $936 million. Latest round: $215 million Series F (April 2023). Key investors include Baillie Gifford, Wellington Management, The Rise Fund (TPG), Fidelity Management & Research, Bain Capital Life Sciences, Janus Henderson Investors.
- Founded
- 2007
- Headquarters
- Redwood City, California, USA
- Team size
- 501-1000
- Total funding
- Over $936 million
Value proposition
Enables precise diagnosis and treatment planning for coronary artery disease without invasive procedures, reducing unnecessary diagnostic angiograms, lowering costs, and improving patient outcomes.
Products and solutions
Heartflow FFRct Analysis, Heartflow Plaque Analysis, Heartflow RoadMap Analysis
Unique value
The first and only company to offer a non-invasive, AI-driven FFRct (Fractional Flow Reserve from CT) analysis that provides a functional assessment of coronary artery blockages from a standard CT scan.
Target customer
Hospitals, cardiologists, and radiologists specializing in cardiovascular diagnostics.
Industries served
Healthcare, Medical Diagnostics
Technology advantage
Combines deep learning with computational fluid dynamics to create a personalized 3D model of the heart, reducing the need for invasive procedures by over 83% and providing a clear, data-driven pathway for patient care.
How they differentiate
HeartFlow's primary differentiator is its focus on functional assessment (blood flow) via FFRct, whereas competitors primarily focus on anatomical analysis (plaque characterization and quantification).
Main competitors
Cleerly, Artrya, Philips (through its acquisition of Circle CVI), CathWorks, Vista.ai, inHEART
Key partnerships
Siemens Healthineers, NHS England
Notable customers
NHS England, Cleveland Clinic, Mount Sinai Health System, Munson Medical Center, Charleston Area Medical Center
Major milestones
Received FDA clearance for FFRct Analysis (2014), Obtained national recommendation from NICE in the UK, Secured a national contract with NHS England for widespread adoption, Announced a strategic partnership with Siemens Healthineers, FDA clearance for new products including RoadMap Analysis, Plaque Analysis, and Planner (2022-2023), Closed $215 million in Series F funding (2023)
Growth metrics
Technology has been used to manage over 200,000 patients and is adopted in more than 750 hospitals worldwide.
Market positioning
Market leader in non-invasive FFRct analysis, supported by extensive clinical evidence, strong regulatory approvals (FDA, NICE), and significant commercial adoption.
Geographic focus
Global, with a strong presence in the United States, United Kingdom (via a national contract with NHS), Europe, and Japan.
Patents and IP
Holds a significant portfolio of patents related to its FFRct technology, medical image processing, and computational fluid dynamics for cardiovascular applications.
About John Farquhar
Previously served as Executive Chairman at Cydar Medical and held senior executive roles at Medtronic, including Vice President of the Aortic, Peripheral, & embolization businesses.
Official website: https://www.heartflow.com/